A Phase I Open Label Trial of Continuous Dosing With BIBW 2992 Combined With Paclitaxel and BIBW 2992 Combined With Paclitaxel and Bevacizumab, BIBW 2992 Combined With Carboplatin and BIBW 2992 Combined With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Afatinib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 07 Jun 2016 Results (n=38) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 20 Feb 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov
- 07 Jan 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Jan 2015 to 1 Feb 2015.